Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 9/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | MAPK3 | P27361 | 3/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4774902 | 0.80 | MAPK14 (0.48) | MAPK14MAPK1MAPK8MAPK9MAPK10 | |
| SCHEMBL14004218 | 0.76 | HDAC3 (0.46) | MAPK14MAPK1LCKMAPK8MAPK9 | |
| SCHEMBL14004188 | 0.76 | MAPK1 (0.49) | MAPK14MAPK1LCKMAPK8MAPK9 | |
| SCHEMBL4765878 | 0.73 | MAPK14 (0.59) | MAPK14MAPK1LCKMAPK8MAPK9 | |
| SCHEMBL4776152 | 0.72 | MAPK14 (0.53) | MAPK14MAPK1MAPK8MAPK9MAPK10 | |
| SCHEMBL14040923 | 0.72 | MAPK1 (0.42) | MAPK14MAPK1LCKMAPK8MAPK9 | |
| SCHEMBL4765914 | 0.71 | MAPK14 (0.46) | MAPK14MAPK1LCKMAPK8MAPK9 | |
| SCHEMBL4775106 | 0.71 | MAPK14 (0.48) | MAPK14MAPK1LCKMAPK8MAPK3 | |
| SCHEMBL4776143 | 0.71 | MAPK14 (0.44) | MAPK14MAPK1LCKMAPK8MAPK9 | |
| SCHEMBL4770629 | 0.71 | MAPK1 (0.51) | MAPK14MAPK1LCKMAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449472-B2 | Methods of inhibiting p38 with substituted bicyclic pyrimidines | ROCHE PALO ALTO LLC (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449472-B2 | Methods of inhibiting p38 with substituted bicyclic pyrimidines | ROCHE PALO ALTO LLC (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449472-B2 | Methods of inhibiting p38 with substituted bicyclic pyrimidines | ROCHE PALO ALTO LLC (US) | 2008-11-11 | — | — | US | disclosed |
| US-7439247-B2 | Bicyclic pyridine and pyrimidine P38 kinase inhibitors | ROCHE PALO ALTOP LLC (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439247-B2 | Bicyclic pyridine and pyrimidine P38 kinase inhibitors | ROCHE PALO ALTOP LLC (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439247-B2 | Bicyclic pyridine and pyrimidine P38 kinase inhibitors | ROCHE PALO ALTOP LLC (US) | 2008-10-21 | — | — | US | disclosed |
| EP-1485390-B1 | BICYCLIC PYRIDINE AND PYRIMIDINE P38 KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | EP | disclosed |
| EP-1485390-B1 | BICYCLIC PYRIDINE AND PYRIMIDINE P38 KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | EP | disclosed |
| US-7091347-B2 | Bicyclic pyridine and pyrimidine p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060084803-A1 | Bicyclic pyridine and pyrimidine P38 kinase inhibitors | CHEN JIAN J | 2006-04-20 | — | — | US | disclosed |
| US-20050288312-A1 | Bicyclic pyridine and pyrimidine p38 kinase inhibitors | CHEN JIAN J | 2005-12-29 | — | — | US | disclosed |
| US-20030207900-A1 | Bicyclic pyridine and pyrimidine p38 kinase inhibitors | ROCHE PALO ALTO LLC | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288312-A1 | Bicyclic pyridine and pyrimidine p38 kinase inhibitors | MAPK1, MAP3K1, MAP3K8 | MAPK14 46/4885MAPK1 1/4885LCK 112/4885 |
| US-20030207900-A1 | Bicyclic pyridine and pyrimidine p38 kinase inhibitors | MAPK1, MAP3K1, MAPKAPK2 | MAPK14 43/4885MAPK1 1/4885LCK 89/4885 |
| US-20060084803-A1 | Bicyclic pyridine and pyrimidine P38 kinase inhibitors | MAPK1, MAP3K1, MAP3K8 | MAPK14 46/4885MAPK1 1/4885LCK 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.